Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.
Not all profitable companies are created equal, and that’s why we built StockStory - to help you find the ones that truly shine bright. That said, here is one profitable company that balances growth and profitability and two that may face some trouble.
Two Stocks to Sell:
Vontier (VNT)
Trailing 12-Month GAAP Operating Margin: 18.4%
A spin-off of a spin-off, Vontier (NYSE: VNT) provides electronic products and systems to the transportation, automotive, and manufacturing sectors.
Why Do We Pass on VNT?
- Organic sales performance over the past two years indicates the company may need to make strategic adjustments or rely on M&A to catalyze faster growth
- Forecasted revenue decline of 2.3% for the upcoming 12 months implies demand will fall off a cliff
- Earnings growth underperformed the sector average over the last five years as its EPS grew by just 1.2% annually
At $28.18 per share, Vontier trades at 8.2x forward P/E. To fully understand why you should be careful with VNT, check out our full research report (it’s free).
Voya Financial (VOYA)
Trailing 12-Month GAAP Operating Margin: 11.5%
Originally spun off from Dutch financial giant ING in 2013 and rebranded with a name suggesting "voyage," Voya Financial (NYSE: VOYA) provides workplace benefits and savings solutions to U.S. employers, helping their employees achieve better financial outcomes through retirement plans and insurance products.
Why Does VOYA Worry Us?
- Annual revenue growth of 5.5% over the last two years was below our standards for the financials sector
- Earnings per share lagged its peers over the last two years as they only grew by 4.9% annually
- Products and services are facing significant credit quality challenges during this cycle as tangible book value per share has declined by 13.1% annually over the last five years
Voya Financial is trading at $86.69 per share, or 8.7x forward P/E. Read our free research report to see why you should think twice about including VOYA in your portfolio.
One Stock to Watch:
Globus Medical (GMED)
Trailing 12-Month GAAP Operating Margin: 17.2%
With operations spanning 64 countries and a portfolio of over 10 new products launched in 2023 alone, Globus Medical (NYSE: GMED) develops and sells implantable devices, surgical instruments, and technology solutions for spine, orthopedic, and neurosurgical procedures.
Why Are We Fans of GMED?
- Impressive 30.3% annual revenue growth over the last five years indicates it’s winning market share this cycle
- Steady constant currency growth over the past two years shows the company can pursue its global ambitions, even in uncertain economic times
- Earnings growth has massively outpaced its peers over the last five years as its EPS has compounded at 22.2% annually
Globus Medical’s stock price of $79.99 implies a valuation ratio of 16.6x forward P/E. Is now the time to initiate a position? See for yourself in our full research report, it’s free.
High-Quality Stocks for All Market Conditions
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.
